

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-...
Q2 2026
Aug 12, 2026
Q1 2026
May 6, 2026
FY 2025
Mar 11, 2026
Q4 2025
Mar 11, 2026
Q3 2025
Nov 10, 2025